PNRC1 and Alzheimer disease: A large body of evidence, including human genetics, suggests that the deposition of Αβ42 is a key pathogenic event in AD,1 and recently, the monoclonal antibody aducanumab was approved as the first Aβ‐amyloid–directed therapeutic for the treatment of AD.